GPT Healthcare
- P/E
- 23.3x
- 52-week range
- 115 – 175
- ROE
- 17%
- ROCE
- 20%
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
GPT Healthcare Limited is an India-based company. The Company’s principal activities include the operation of multidisciplinary private hospitals and pharmacies. It has four multispecialty hospitals, two in Kolkata, Salt Lake, one in Agartala and one hospital in Howrah, West Bengal, and has one nursing institute in Agartala, under the brand name ILS Hospitals. ILS Hospitals, Agartala, has approximately 205 bedded multispecialty hospital with a 50 Seat B.Sc. Nursing College. ILS Hospitals, Agartala has operating theaters, a catheterization laboratory and other diagnostic and therapeutic equipment. The ILS Hospitals Dumdum has approximately 155 bedded multispecialty hospital with operation theaters, a catheterization laboratory and other diagnostic and therapeutic equipment. ILS Hospitals Howrah is a multi-specialty hospital which is equipped with over 116 beds. ILS Hospitals Salt Lake is a multispecialty hospital with approximately 85 beds and three operation theaters.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →GPT Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)23.3 against a typical 48.9: cheaper than most peers (1st = cheapest).8th of 40
- Sales growth+17.8% against a typical +21.1% from a year earlier.20th of 34
- Profit growth+62.5% against a typical +13% from a year earlier.4th of 31
- Share price, 3 months−19.3% against a typical −10.9%.27th of 34
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Withdrawn | Stable | 27 Oct 2025 |
Every agency has withdrawn its rating.
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 27 Oct 2025 | Withdrawn | was Crisil A- | — | CRISIL | ₹ 67.71 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2026 and dividend |
| 3 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 18 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 2 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 8 Nov 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2025 and dividend |
| 6 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 23 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108 | 97 | 99 | 98 | 106 | 102 | 101 | 107 | 119 | 120 | 126 | 126 |
| Expenses | 83 | 76 | 76 | 80 | 82 | 81 | 81 | 90 | 96 | 99 | 103 | 102 |
| Operating Profit | 25 | 21 | 23 | 18 | 23 | 21 | 21 | 17 | 23 | 21 | 23 | 24 |
| OPM % | 23% | 22% | 23% | 18% | 22% | 21% | 20% | 16% | 19% | 17% | 18% | 19% |
| Other Income | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 |
| Interest | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | 19 | 16 | 18 | 15 | 21 | 18 | 16 | 11 | 15 | 13 | 16 | 17 |
| Tax % | 31% | 28% | 30% | 32% | 28% | 30% | 21% | 31% | 30% | 27% | 8% | 26% |
| Net Profit | 14 | 11 | 13 | 10 | 15 | 12 | 13 | 8 | 11 | 9 | 15 | 13 |
| EPS in Rs | 1.69 | 1.44 | 1.56 | 1.21 | 1.81 | 1.49 | 1.57 | 0.94 | 1.29 | 1.14 | 1.78 | 1.55 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 9%
- TTM
- 18%
- 10 Years
- —
- 5 Years
- 16%
- 3 Years
- 4%
- TTM
- −1%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 22%
- 3 Years
- 21%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| GPT Healthcare | ₹ 135.00 | — | 23.3x | — | 17% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Kriti Tantia
- Chief Financial Officer
- Ankur Sharma
- Compliance Officer, Company Secretary
- Om Tantia
- Managing Director, Executive Director
- Anurag Tantia
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.